<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148393</url>
  </required_header>
  <id_info>
    <org_study_id>2014-128</org_study_id>
    <secondary_id>2014-001480-12</secondary_id>
    <nct_id>NCT02148393</nct_id>
  </id_info>
  <brief_title>Implantation Enhancement by Elective Cryopreservation of All Viable Embryos</brief_title>
  <acronym>ICE</acronym>
  <official_title>Elective Blastocyst Vitrification for Endometrial Receptivity Enhancement in High-responder Patients Undergoing in Vitro Fertilisation/Intracytoplasmatic Sperm Injection (IVF/ICSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised controlled open-label clinical trial to compare the clinical pregnancy rates&#xD;
      between fresh embryo transfer and elective all-embryo vitrification with thawing and transfer&#xD;
      in a subsequent cycle in high-responders&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two-arm randomised, single-centre, controlled open-label trial. Summarily, women undergoing&#xD;
      exogenous gonadotropin ovarian stimulation for ART in a gonadotropin-releasing hormone (GnRH)&#xD;
      antagonist down-regulated cycle and at high risk for ovarian hyperstimulation syndrome (OHSS)&#xD;
      will be included in either the control (&quot;fresh embryo transfer&quot;) or intervention (&quot;subsequent&#xD;
      vitrified-warmed embryo transfer&quot;) groups. Women in the control group will undergo GnRH&#xD;
      agonist triggering followed by intensified luteal phase support while the intervention group&#xD;
      will electively vitrify all viable embryos after GnRH triggering and perform the embryo&#xD;
      transfer (ET) in a subsequent unstimulated cycle.&#xD;
&#xD;
      Ovarian stimulation, ultrasound and hormonal monitoring, ovulation induction, oocyte&#xD;
      retrieval, embryology procedure, IVF and luteal support will be according to how they are&#xD;
      normally performed in our centre.&#xD;
&#xD;
      All women included will undergo artificial ovarian stimulation with GnRH antagonist&#xD;
      down-regulation with daily injections of either ganirelix (Orgalutran®) or cetrorelix&#xD;
      (Cetrotide®). Treating physicians will opt on which exogenous gonadotropins should be used&#xD;
      according to the patient's profile and preference and can include either recombinant follicle&#xD;
      stimulating hormone (FSH) or highly purified urinary human menopausal gonadotropin (HP-HMG).&#xD;
      Ovarian stimulation will commence after it is confirmed that the patient is not pregnant and&#xD;
      has basal levels of oestradiol, progesterone, FSH and luteinising hormone (LH). The&#xD;
      stimulation will be monitored simultaneously by pelvic ultrasound and hormonal analyses&#xD;
      (oestradiol, progesterone), starting on day 7 of stimulation and then every 1 to 3 days,&#xD;
      according to the individual endocrine profile and follicular development.&#xD;
&#xD;
      Final oocyte maturation will be triggered with 0.2 mg triptorelin (Decapeptyl®, Gonapeptyl®)&#xD;
      as soon as 3 follicles of ≥17 mm are observed. A GnRH agonist will be the preferred&#xD;
      triggering agent for both groups to reduce the risk of severe OHSS associated with human&#xD;
      chorionic gonadotropin (hCG) triggering in high-responders. Oocyte retrieval will be&#xD;
      performed 36 hours after hCG administration under either local anaesthesia with analgesic&#xD;
      premedication or general anaesthesia, according to patient preference.&#xD;
&#xD;
      IVF/ICSI will be performed, using the specimen of sperm made available by the male progenitor&#xD;
      on the day of oocyte retrieval.&#xD;
&#xD;
      The choice to transfer one or two embryos will be decided by the clinician at consultation&#xD;
      mainly depending on the patient's age and the number of embryos replaced in the previous&#xD;
      treatment cycles, according to Belgian law.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rates</measure>
    <time_frame>7 weeks</time_frame>
    <description>Pregnancy visible under transvaginal pelvic ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian hyperstimulation syndrome incidence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Observation of early-onset ovarian hyperstimulation syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Infertility</condition>
  <condition>OHSS</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control group, following oocyte retrieval, intensified luteal phase support for fresh embryo transfer (with Pregnyl®, Utrogestan® and Progynova®) will be performed. Fresh ET in the uterine cavity will be performed on the 5th day of embryo development at blastocyst stage under ultrasound guidance whenever possible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elective vitrification with subsequent-cycle embryo thawing/transfer (CryoBioSystem®) will be performed. Hence, no luteal phase support will be provided immediately after oocyte retrieval. Instead, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.&#xD;
On the day of embryo transfer, blastocyst(s) will be warmed one by one until one or two blastocysts are suitable for transfer. ET to the uterine cavity will be performed under ultrasound guidance whenever possible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrification with subsequent-cycle embryo thawing/transfer</intervention_name>
    <description>The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).&#xD;
In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intensified luteal phase support for fresh embryo transfer</intervention_name>
    <description>A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnyl®</intervention_name>
    <description>1500 IU</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>hCG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Utrogestan®</intervention_name>
    <description>200 mg tid</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Vaginal progesterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progynova®</intervention_name>
    <description>2 mg bid</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Estradiol valerate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CryoBioSystem®</intervention_name>
    <description>CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First or second IVF/ICSI cycle&#xD;
&#xD;
          -  High response to ovarian stimulation (defined as presence of ≥18 follicles of ≥11 mm&#xD;
             on the day of GnRH triggering)&#xD;
&#xD;
          -  GnRH antagonist down-regulation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients can be included only once in the trial&#xD;
&#xD;
          -  Planned replacement of 1 or 2 blastocysts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting&#xD;
             the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial&#xD;
             tuberculosis)&#xD;
&#xD;
          -  Oocyte/embryos donation acceptors&#xD;
&#xD;
          -  Embryos planned to undergo preimplantation genetic diagnosis/screening&#xD;
&#xD;
          -  Body mass index ≥35 or ≤18&#xD;
&#xD;
          -  Women who have previously enrolled in the trial&#xD;
&#xD;
          -  Those unable to comprehend the investigational nature of the proposed study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Santos-Ribeiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Blockeel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <state>Lisboa</state>
        <zip>1600-548</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.brusselsivf.be/default.aspx?lang=EN</url>
    <description>Centre for Reproductive Medicine</description>
  </link>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Samuel Santos-Ribeiro</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

